WebBackground: PD-1/PD-L1 engagement and overexpression of galectin-3 (Gal-3) are critical mechanisms of tumor-induced immune suppression that contribute to immunotherapy resistance. We hypothesized that Gal-3 blockade with belapectin (GR-MD-02) plus anti-PD-1 (pembrolizumab) would enhance tumor response in patients with metastatic melanoma … WebMar 2, 2024 · Galectin's lead drug, belapectin (GR‑MD‑02), is a carbohydrate-based drug that inhibits the galectin‑3 protein, involved in many inflammatory, fibrotic, and malignant … A previous clinical trial showed belapectin may prevent the development of … Belapectin: NASH Cirrhosis NASH Advanced Fibrosis Lung, Kidney … Galectin Therapeutics Street Address: 4960 Peachtree Industrial Boulevard Suite … Galectins are widely studied, with nearly 3,500 scientific publications with … Our compounds act as galectin inhibitors, binding to galectin proteins and … Galectin Therapeutics has also worked closely with Kevin Mayo at the … Galectin Therapeutics’ drug candidates in development are new chemical entities … The NAVIGATE Study is an international, seamless, adaptively-designed Phase … Galectin Therapeutics leverages extensive scientific and development expertise as … Leadership Galectin Therapeutics Inc.
Belapectin, Pembrolizumab Show Early Activity, Tolerability in ...
WebGalectin Therapeutics has started recruiting NASH patients with compensated cirrhosis for a Phase 2b/3 NAVIGATE clinical study (ClinicalTrials.gov NCT04365868) to begin evaluating the safety and efficacy of Belapectin (GR-MD-02), a complex carbohydrate that targets Galectin-3, a β‐galactoside‐binding lectin that plays an important role in ... WebGALT Galectin Therapeutics Inc Galectin Therapeutics Reports Fiscal 2024 Financial Results and Provides Business Update NORCROSS, Ga., March 31, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and... fetzer logo
Corporate Update –focused on NASH Cirrhosis
WebJul 16, 2024 · Belapectin is a complex carbohydrate drug that targets galectin-3, which is a protein that plays an important role in the pathogenesis of NASH and fibrosis. Moreover, galectin-3 is involved in diseases like fibrotic disorders of the liver, lung, kidney, heart, and vascular system. The agent binds to galectin-3 and interrupts its function. WebGalectin’s lead drug belapectin (formerly known as GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in non-alcoholic ... WebMar 2, 2024 · Belapectin is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of NASH and fibrosis. Galectin-3 plays a major role in diseases that involve scarring of organs, including fibrotic disorders of the liver, lung, kidney, heart and vascular system. Belapectin binds to galectin-3 and disrupts its function. fetzer rad